Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17570951 | 1.00 | FAAH (0.50) | FAAHSMN1; SMN2SLC6A5TSHRALDH1A1 | |
| SCHEMBL18924154 | 0.86 | FAAH (0.43) | FAAHSMN1; SMN2SLC6A5TSHRALDH1A1 | |
| SCHEMBL17570945 | 0.86 | FAAH (0.43) | FAAHSMN1; SMN2SLC6A5TSHRALDH1A1 | |
| SCHEMBL22019559 | 0.86 | TSHR (0.42) | FAAHTSHRALDH1A1LMNARECQL | |
| SCHEMBL22019557 | 0.86 | TSHR (0.42) | FAAHTSHRALDH1A1LMNARECQL | |
| SCHEMBL25052997 | 0.85 | FAAH (0.54) | FAAHSMN1; SMN2SLC6A5ALDH1A1LMNA | |
| SCHEMBL21549707 | 0.84 | FAAH (0.51) | FAAHSMN1; SMN2SLC6A5TSHRALDH1A1 | |
| SCHEMBL21585637 | 0.83 | FAAH (0.69) | FAAHSMN1; SMN2SLC6A5ALDH1A1MAPT | |
| SCHEMBL10723213 | 0.83 | FAAH (0.69) | FAAHSMN1; SMN2SLC6A5ALDH1A1MAPT | |
| SCHEMBL21585636 | 0.83 | FAAH (0.69) | FAAHSMN1; SMN2SLC6A5ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233697-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-07-27 | — | — | US | disclosed |
| US-11116845-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200405870-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2020-12-31 | — | — | US | disclosed |
| US-10722588-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190269786-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2019-09-05 | — | — | US | disclosed |
| US-10238751-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20170340748-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9669102-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160082114-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2016-03-24 | — | — | US | disclosed |
| WO-2016036801-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. (US) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10238751-B2 | Cytotoxic benzodiazepine derivatives | GABRA6, GABBR1, GABRA5 | FAAH 2111/4885SMN1; SMN2 2324/4885SLC6A5 1022/4885 |
| US-11116845-B2 | Cytotoxic benzodiazepine derivatives | GABRA6, GABBR1, GABRA5 | FAAH 2111/4885SMN1; SMN2 2324/4885SLC6A5 1022/4885 |
| US-20200405870-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | FAAH 2111/4885SMN1; SMN2 2324/4885SLC6A5 1022/4885 |
| US-20230233697-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | FAAH 2111/4885SMN1; SMN2 2324/4885SLC6A5 1022/4885 |
| US-20160082114-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | FAAH 2111/4885SMN1; SMN2 2324/4885SLC6A5 1022/4885 |
| US-10722588-B2 | Cytotoxic benzodiazepine derivatives | GABRA6, GABBR1, GABRA5 | FAAH 2111/4885SMN1; SMN2 2324/4885SLC6A5 1022/4885 |
| US-20190269786-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | FAAH 2111/4885SMN1; SMN2 2324/4885SLC6A5 1022/4885 |
| US-20170340748-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | FAAH 2111/4885SMN1; SMN2 2324/4885SLC6A5 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.